ORS-1006

ORS-1006 is an orally available small-molecule protein kinase inhibitor that was developed by Arrien Pharmaceuticals as a first-in-class therapy targeting kinase pathways implicated in Parkinson’s disease and other central nervous system disorders. Public pipeline summaries describe it as a DYRK1A inhibitor, while company communications highlight activity against LRRK2-mediated Parkinson’s disease biology, indicating a strategy focused on disease-modifying kinase targets in neurodegeneration.[3][5][7][11] ORS-1006 progressed in preclinical and early development but was ultimately discontinued without reaching regulatory approval.